Editing Indapamide (section)

== Medical uses ==
Its indications include hypertension and edema due to congestive heart failure. Indapamide has been shown to reduce stroke rates in people with high blood pressure.<ref name="Beckett_2008" /><ref>{{cite journal | vauthors = Liu L, Wang Z, Gong L, Zhang Y, Thijs L, Staessen JA, Wang J | title = Blood pressure reduction for the secondary prevention of stroke: a Chinese trial and a systematic review of the literature | journal = Hypertension Research | volume = 32 | issue = 11 | pages = 1032–1040 | date = November 2009 | pmid = 19798097 | doi = 10.1038/hr.2009.139 | doi-access = free }}</ref><ref name="PROGRESS Collaborative Group_2001">{{cite journal | vauthors = ((PROGRESS Collaborative Group)) | title = Randomised trial of a perindopril-based blood-pressure-lowering regimen among 6,105 individuals with previous stroke or transient ischaemic attack | journal = Lancet | volume = 358 | issue = 9287 | pages = 1033–1041 | date = September 2001 | pmid = 11589932 | doi = 10.1016/s0140-6736(01)06178-5 | s2cid = 10053225 }}</ref> Studies have shown that the blood pressure lowering effects of indapamide in combination with perindopril reduce the rate of stroke in high risk patients (those with a history of high blood pressure, stroke or type two diabetes).<ref name="Beckett_2008" /><ref name="PROGRESS Collaborative Group_2001" /><ref>{{cite journal | vauthors = Patel A, MacMahon S, Chalmers J, Neal B, Woodward M, Billot L, Harrap S, Poulter N, Marre M, Cooper M, Glasziou P, Grobbee DE, Hamet P, Heller S, Liu LS, Mancia G, Mogensen CE, Pan CY, Rodgers A, Williams B | display-authors = 6 | title = Effects of a fixed combination of perindopril and indapamide on macrovascular and microvascular outcomes in patients with type 2 diabetes mellitus (the ADVANCE trial): a randomised controlled trial | journal = Lancet | volume = 370 | issue = 9590 | pages = 829–840 | date = September 2007 | pmid = 17765963 | doi = 10.1016/s0140-6736(07)61303-8 | s2cid = 21153924 }}</ref> HYVET study showed that indapamide (sustained release), with or without perindopril as antihypertensive treatment in persons 80 years of age or older with sustained systolic blood pressure of 160 mmHg or higher, demonstrated significant reduction in all-cause mortality when treated to a target of 150/80 mmHg, but there was found to be no significant reduction in risk of death from cardiac causes.<ref name="Beckett_2008" /> Two systematic reviews identified that indapamide with or without perindopril significantly reduced all cause mortality in young-elderly patients with a history of stroke, cardiovascular disease and type 2 diabetes mellitus, when greater reductions in mean office blood pressure are achieved, significant cardiovascular benefit was only observed when trials including the >75 years old cohort was included.<ref name="Beckett_2008" /><ref>{{cite journal | vauthors = Olde Engberink RH, Frenkel WJ, van den Bogaard B, Brewster LM, Vogt L, van den Born BJ | title = Effects of thiazide-type and thiazide-like diuretics on cardiovascular events and mortality: systematic review and meta-analysis | journal = Hypertension | volume = 65 | issue = 5 | pages = 1033–1040 | date = May 2015 | pmid = 25733241 | doi = 10.1161/HYPERTENSIONAHA.114.05122 | doi-access = free }}</ref><ref>{{Cite journal| vauthors = Chalmers J, Mourad JJ, De Champvallins M, Mancia G |title=Benefit of Indapamide-Based Treatment on Mortality|date=July 2019|journal=Journal of Hypertension|language=en-US|volume=37|pages=e57|doi=10.1097/01.hjh.0000570928.33807.a8|issn=0263-6352|doi-access=free}}</ref>